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There is concern about possible association between
PUVA treatment and an increased risk ofnoncutane-
ous cancer. An alteration in the risk of cancer among
persons with psoriasis has also been postulated. To
test this hypothesis, for nearly two decades we have
prospectively followed 1380 pati,ents who first began
PUVA treatment for psoriasis in 1975-1976. We com-
pare the risk of noncutaneous cancer in our cohort
with that expected based on general population inci-
dence rates. The overall risk of noncutaneous cancer
was nearly identical to that expected in general pop-
ulation. For three separate sites, we noted significant
increases: thyroid cancer (RR = 3.57, 95% CI =
1.16-8.34), breast cancer (RR = 1.81, 95% CI =
Since Parrish cl at (1974) first demonstrated the efficiencyof oral 8-methoxypsoralen and ultraviolet-A (PUVA) inthe treatment of psoriasis, it has become a widelyutilized treatment for psoriasis and other skin diseases.Although many years ago, some clinicians hypothesized
that psoriasis may protect from cancer (Chapman et ai, 1978;
Shuster ct ai, 1979), subsequent population based studies have
suggested that the risk of some types of noncutaneous cancers may
be elevated among persons with psoriasis (Lindegard, 1986; Lin-
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1.19-2.64), and central nervous system neoplasms
(RR = 2.80, 95% CI = 1.13-5.57). Since 1987, how-
ever, the risk of central nervous system neoplasms
has not been elevated (RR = 0.00, 95% CI = 0.00-
3.35) and the relative risk of breast cancer was lower
than in the prior decade and not statistically signifi-
cant. There was no association between higher levels
of exposure to PUVA and the risk of any of these
cancers. We did not detect any significant increase in
the risk of lymphoma or leukemia. Our study does
not support the hypothesis that long-term PUVA
treatment increases the risk of noncutaneous cancer.
Key words: ll.OllC/l.taneo/l.S callcer/psOI'alell.f//lUI'aviolet A/co-
Ilort st/ldy. ] ltlVest Dem.atol 108:897-900, 1997
delcf et ai, 1990; LindelOf, 1991; Olsen et ai, 1992). Psoralen and
ultraviolet-A radiation are mutagenic and may have immunosup-
pressive effects (Kraemer et ai, 1981; Moscieki et aI, 1982; Bredberg
et ai, 1983). Long-tenn PUVA treatment increases the risk of
squamous cell cancer (Stern et ai, 1984, 1994). Because of those
observations, there was concern that an increased risk of noncuta-
neous cancer, especially Iymphoreticular malignancy, might be a
long-term adverse effect of PUVA.
Since their initial treatment with PUVA in 1975 or 1976, we
have prospectively studied 1380 patients with psoriasis who en-
rolled in a 16-center study. During the first 10 y of study of this
cohort, the overall incidence of noncutaneous cancer did not differ
from expected for the general population for this period (Stem et ai,
1988). We did, however, note an increased risk of central nervous
system neoplasms. We present herein data from 10 Y of additional
prospective study that demonstrate that PUVA treatment is not
associated with an increased t1sk ofnoncutaneous cancer and that in
patients with psoriasis the risk of cancer does not differ substantially
from that of other persons.
MATERIALS AND METHODS
For two decades we have prospectively studied :1 cohort of 1380 patients.
These patients enrolled in the original 16-center stlldy of PUVA therapy.
They were first treated in 1975-76. Patients are followed irrespective of
their continued use of PUVA. OllT study methods have been previously
detailed (Stern el a[, 1984, 1988, 1990, 1994). We conducted annual
interviews that. ask abOut paticnts' health and use of medical services. We
attempted to confirm cancer diagnosis by pathology report, discharge
summary. or death certificate. Each primary cancer was separately consid-
ered. For tumors reported by patients since our last report we have
confirmed 80% from medical records. Of those with an available record,
type of cancer reported by the patient and confirmed by the medical record
were the same i11 99';'0 of the cases. There are two other cases for which the
type of cancer is not definitivd)' diagnosed. We compared the relative risk
of various nonclitancous cancerS in our cohort with the incidence expected
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Table I. Observed and Expected Number of
NOl1cutancous Canccr with RR and 95% CI in PUVA
Paticnts from 1975 to 1996
Site of Observed Expected
Cancer (no.) (no.) R.R. 95'/., CI
All sites 195 181.3 1.08 0.93-1.24
GI tract" 45 37.4 1.20 0.88-1.61
R.esp. tract 37 35.4 1.05 0.74-1.44
Breast 27 14.9 1.81 1.19-2.64
FClllale genitals 6 7.2 0.83 0.31-1.81
Male genitals" 24 35.7 0.67 0.43-1.00
Urinary tract 18 15.4 1.17 0.69-1.85
CNS 7 2.5 2.80 1.13-5.77
Thyroid 5 1.4 3.57 1.16-8.34
Lymphoma 6 6.8 0.88 0.32-1.92
Leukemia 6 4.6 1.30 0.48-2.84
Others 14
" GI, gtlstrointcstinn) tract; eNS. centr;,1 nervous system; Resp., respiratOry.
/. Excludes squnmous cell carcinoma of penis and scrotum.
in the general population overall and for the period since over first report
(September 1, 1986, to February 29, 1996).
For statistical analysis, we calculated the number of expected systemic
cancers on the basis of age-specific data fiom the Surveillance Epidemiol-
ogy, and End Resu)ts program of the National Cancer Institute (SEER,
J995). This federal program calculates cancer incidence rates based on data
collected fi'om population-based cancer registries (Srivastava eI ai, 1992).
We used age- and sex-specific incidence rates for white people for each year
from 1975 to 1.992. To calculate the expected number of tumors for 1993
to 1996, we lISed 1992 incidence rates (program public use, SEER., 1995).
On the basis of the number of observed and expected cancers, we calculated
the incidence rate ratios and used the Poisson distribution to calculate exact
confidence intervals (CIs) (Gahlinger and Abramson, 1993).
RESULTS
From the time of enrollment in the study (1975-1976) to February
29,1996, our cohort of1380 persons had developed a totBl of195
systemic CBncers Bnd one benign central nervous system neoplasm.
At the time of enrollment, the Bverage age was 44 y and 65% of
people were male. Eleven patients developed more than one
primary noncutaneous cancer. By February 29, 1996, 396 were
known to have died. This number of deaths is not substantia.lly
different than that expected based on mortality data for the U.S.
white population. For the remaining 984, follow-up rates for each
interview average more than 90%. For survivors, the median
follow-up time was 19.2 y. This study includes 22,104 person years
of prospective study.
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Table I summarizes the site-specific, observed, and expected
number of tumors and the relative risk (RR) for each anatomic site.
As in the fmt lOy, from 1987 to 1996 the overall incidence of
noncutaneous 'cancer in our cohort was nearly identical to that
expected fi'om population incidence data (R..R. = 1.00; 95% CI =
0.80-1.22). The relative risk of malignant central nervous system
neoplasms, breast cancer, and thyroid cancer were significantly
increased for the study period as a whole. The risk of having male
genital system cancer excluding squamous cell cancer of the penis
and scrotum was decreased, but not significantly. We did not detect
any substantial or significant alteration in the risk of cancer of any
other site.
As detailed in Table II, during the first decade of prospective
study of tlus cohort, its risk of cancer of the central nervous system,
gastrointestinal tract, and female breast were significantly in-
creased. In tlus period we detectcd scven central nervous system
tumors with 1.4 tumors expected. The risk of central nervous
system neoplasms was most notable (RR = 5.0). In the decade
since 1987, we detected only one spinal tumor, wluch is lughly
likely to be a metastatic tumor, and one benign meningioma
(expected = 1.1).
The point estimate of the relative risk of the breast cancer was
elevated in both periods, and this risk was significantly elevated for
the study period as a whole. In the later period, the risk of male
genital tumors, excluding squamous cell cancer of the penis and
scrotum, was significBntly lower number than expected. We did
not detect any significant increase in thc risk of lymphoma,
leukemia, or cancer for any other site, either overall or in the mOSt
recent period.
Since the study began, we ascertained five patients with thyroid
cancer (R..R. = 3.57). Therefore, for the entire study thyroid cancer
now has the greatest increase in risk. Four of the thyroid cancers
were papillary carcinoma, the most common subtype of thyroid
cancer. The mean age at diagnosis was 45 y and 60'1'0 were female.
None of these patients had more than 300 PUVA treatments and
only one person had radiation exposure. None had previou
methotrexate treatment. Two of these patients also recorded other
noncutaneous cancer (pancreas and cecum cancer). From 1975 to
1987, the incidence of thyroid cancer was not significantly elevated
(RR = 2.5; 95% CI = 0.30-9.03). In the last 1.0 y, three cases were
detected (RR = 5.00; 95% CI = 1.03-14.61).
DISCUSSION
This report documents occurrence of the !]oncutaneous cancer
among members of the PUVA follow-up study during two decades
of prospective study. We prescnt data from an additional decade of
foLlow-up since our last report. Our d'lta demonstrate that long_
Table II. Observed and Expected Nutnber of Noncutaneous Canccr with RR and 95°1.. CI in PUVA Patients by 10-y
Period
1975-1986 1987-1996
Site of Observed Expected Observed Expected
cancer (no.) (no.) RR 95% CI (no.) (no.) RR 95% CI
All sites 103 89.1 1.16 0.94-1.40 92 92.2 1.00 0.80-1.22
GI tract" 26 19.8 1.31 0.86-1.92 19 17.6 1.08 0.65-1.67
Resp. tract 17 18.8 0.90 0.52-1.45 20 16.6 '1.21 0.74-1.86
Breast 17 7.4 2.30 1.33-3.68 10 7.5 1.33 0.64-2.45
Female genitals 4 4.1 0.98 0.26-2.50 2 3.1 0.65 0.08-2.33
Male genitals" 11 12.5 0.88 0.44-1.58 13 23.2 0.56 0.30-0.96
Urinary tract 8 7.8 1.03 0.44-2.02 10 7.6 1.32 0.63-2.42
CNS 7 1.4 5.00 2.01-10.30 0" 1.1 0.00 0.00-3.35
Thyroid 2 0.8 2.50 0.30-9.03 3 0.6 5.00 1.03-14.61
Lymphoma 2 3.4 0.59 0.07-2.13 4 3.4 1.18 0.32-3.01
Leukemia 2 2.5 0.80 0.10-2.89 4 2.1. 1.31 0.52-4.88
Others 7 7
., GJ, gastrointestinal; n...csp., respiratory; NS. central nervous system.
'I Excludes squamous cell carcinoma of penis and scrotulIl.
r We noted on benign central nervous ncoplasll'l.
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term PUVA treatment is not associated witb an overall increased
risk of noncutaneous cancer. In fact, tbe incidence of noncutaneous
cancer was nearly identical to that expected /i'om general U.S.
population incidence rates. The tehltion between psoIiasis and
cancer risk overall or site-specifIc risk is controversial. Up to 1980
one group postulated that psoriasis might protect from cancer
(Chapman e( ai, 1978; Shuster eI ai, 1979). Subsequently, increased
risk ofcancer at certain sites has been linked to psoriasis (Lindegard,
1986; LindelOf el al. 1990; LindelOf, 1991; Olsen el ai, 1992). Given
the size of our cohort and nearly 20 y of study, our f1l1dings exclude
more than a small difference in overall cancer risk between Dur
cohort and the general population.
In our earlier report, that described the cohort's experience in its
first decade after exposure to PUVA we noted a 5-fold increase in
tbe risk of central nervous system neoplasms (Stern et ai, 1988).
Since 1987, only Dne (prob:lbly metastatic) malignant central
nervous system neoplasm was detected. Therefore, the elevated
risk of central nervous system neoplasms we noted in the first
decade has not been confirmed. Because of the effect ofPUVA Dn
lymphocytes. from the inception of the study we were concerned
about the possibility of an increased risk of leukemia and lympho-
mas with long-term PUVA (Kr<lemer et al., 1981; Moscicki eI ai,
1982). Our f<lUure to detect any signiticant increase in the risk of
lymphoma or leukemia is re<lssuring.
We did note an increased incidence of thyroid cancer. In an
atten'lpt tD determine risk filctDrs that cDuld predispose to this
cancer we examined exposure to ionizing radiation, number of
PUVA treatments, and use of methotrexate. Thyroid cancer cases
did not have greater exposure to these treatments than the overa.ll
frequency of those exposure in our cohort. Only one patient with
thyroid cancer recorded exposure to ionizing radiation for treat-
ment of her psoriasis. The risk of developing thyroid cancer after
radiation exposure is well documented (Maxon, 1985; Schneider et
01,1993).
Overall, we noted a modest and significant overall incidence in
the risk of breast canceL For the last lOy, the incidence of breast
cancer was not, however, significantly increased and the point
estin'late of IUz. was lower than during the first 10 Y of the study
(Stern et ai, J 988). These findings may reflect a number of f..ctors.
Another study demonstrated an increased risk of breast cancer in
males with psoriasis but not females. This increase in risk did not
appear t'elated to exposure to any specific treatment for psoriasis
(Lindelof, 1991). All Dur breast cancer cases, however, were
female. Some groups ofJewish women have a higher risk of breast
cancer than the general white pDpulation (Egan et ai, 1996). Our
cohort, which included a disproportionate number Df centers
located in cities with larger than average Jewish populations, is
likely to have a larger proportion of Jewish people than for the
United States as a whole. Therefore, increased susceptibility may be
one explanation of the increased breast cancer risk. ArguiJlg against
this expla.nation is that the gene mutation linked to breast cancer
risk in Jewish women has also been linked tD ovarian cancer, and
we did not detect any excess in female genital tract tumors in our
cohort (Fitzgerald et ai, 1996). The most likely reason for the
increased incidence in the first but not second decade of follow up
is ascertainment bias or chance. Individuals entering the trial were
likely to come under closer medical supervision and preexisting
early tumors might be more likely to be detected. Although the
number of examinations offered to participants by the study was
higher in the first than second decade of follDw up. the only study
sponsored examinations were of the skin and eye. The decrease in
relative risk in the second compared to the first decade after study
entry (and no longer significant fOl' the second decade) of breast
cancer in our cohort and the lack association between the devel-
opment of breast cancer and higher exposure to PUV A lead us to
believe that factors other than PUVA exposure account for the
increase we observed.
Multiple European studies have demonstrated an association
benveen psoriasis and an increased risk of respiratory tract cancers
(LindelOf et (/1, 1990; Olsen et ai, 1992). Lung cancer risk is
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increased among cigarette smokers (Boucot ct ai, 1966). Some
surveys suggest persons with psoriasis smoke more frequently than
the general population (Naldi et ai, 1992). In our cohort the risk of
having lung cancer does not differ from expected based on U.S.
population. We examined smoking habits of our cohort. Among
men the prevalence of smoking was slightly lower than for the
general U.S. population, and female members of our cDhort
smoked only slightly more often than does the general female
population of the United States (U.S. Depa.rtment of Health,
Education, and Welfare, 1979).
Associ:ltion between psoriasis and colon cancer has been detected
in many previous studies (Stem et ai, 1988; Lindelof et ai, 1991;
Olsen el ai, 1992). Altbough we noted a significant increase in the
incidence of gastrointestinal tumors ITDm 1975 to 1987, our
subsequent data do not confirm this fmding. NoncuC<lI1eous malig-
nancies have been reported in patients treated with immunosup-
pressive drugs such as cyclDspOlin and methotrexate (Penn., 1978;
Trenkwalder ct ai, 1992). There are, however, no population-based
studies showing increased risk of malignant tumDrs with lDw-dose
methotrexate use (Stern et ai, 1982). Therefore, we believe that the
claims of these case reports and small series are more likely to reflect
chance or exposure to carcinogens other than PUV A.
A comparison of the published results of the first decade and
these results from the second decade l'eveal some discrepancies.
These discrepancies reflect factors including information received
since our last publication that lead to reclassifying some tumDrs and
our use of incidence data that spanned a longer period than the
incidence data available tD us in 1987 (Stem et ai, 1988).
Our current data, wh.ich spans nearly two decades of prospective
study, do not support the hypothesis that long-term POYA treat-
ment increases the lisk of noncutaneous cancer or that persons with
psoriasis have <In altered risk of cancer. When combined with our
observations of greatly increased risk of squamous cell cancer of the
skin among members of this cohort exposed to high doses of
PUV A, our data suggest that the carcinDgenic effect of POYA is
limited to tlle skin. We will continue to mDnitor our cobort for the
occurrence of noncutaneous cancer, especially the development of
thyrDid cancer, the only noncutaneous malignancy with a substan-
tially increased and increasing risk tint we have observed after two
decades of prospective study, and Iymphoreticular malignancy, the
tumDr for which, based on experimental data, our concern was
greatest (Kraemer el 01. 1981; Bredberg ('I ai, l 983).
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